In the SOLO-1 trial, olaparib was tested as a frontline maintenance treatment in women with newly diagnosed FIGO stage III–IV ovarian cancer with germline or somatic BRCA1/2 mutation following cytoreductive surgery and platinum-based chemotherapy. This evidence concerns the gene BRCA1 and ovarian carcinoma.